{"gene":"SLC16A3","run_date":"2026-06-10T07:46:32","timeline":{"discoveries":[{"year":2013,"finding":"DNA methylation of the SLC16A3 promoter regulates MCT4 expression in renal cancer; promoter activity assays in RCC cell lines confirmed that methylation at specific CpG sites suppresses SLC16A3/MCT4 transcription.","method":"Promoter activity assays in RCC cell lines, correlation of CpG methylation with mRNA expression in patient cohorts","journal":"Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assays in four cell lines, validated in three independent cohorts, single lab","pmids":["23881922"],"is_preprint":false},{"year":2016,"finding":"MCT4 (SLC16A3) mediates l-lactate transport in Caco-2 cells; diclofenac non-competitively inhibits MCT4-mediated l-lactate uptake with an inhibition constant of 20 µM, validated in Xenopus oocyte expression system.","method":"Radiolabeled l-lactate uptake assay in Caco-2 cells, kinetic inhibition analysis, Xenopus oocyte expression system","journal":"Drug Metabolism and Pharmacokinetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro transport assay with kinetic analysis plus orthogonal Xenopus oocyte validation, single lab","pmids":["27236641"],"is_preprint":false},{"year":2016,"finding":"Butyric acid upregulates SLC16A3 (MCT4) protein and mRNA in Caco-2 cells; MCT4 localizes exclusively to the lateral plasma membrane and functions as a basolateral efflux transporter for ferulic acid, while MCT1 mediates apical uptake.","method":"mRNA/protein quantification, immunofluorescence localization, transepithelial transport assays in Caco-2 cells","journal":"Archives of Biochemistry and Biophysics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by immunofluorescence tied to functional transport assay, single lab","pmids":["26854723"],"is_preprint":false},{"year":2019,"finding":"Under hypoxia, HIF-1α directly activates SLC16A3 transcription by binding a hypoxia-response element (HRE) in the promoter; FBI-1 (ZBTB7A) represses SLC16A3 by binding FREs and HREs. NF-κB (RelA/p65) represses ZBTB7A transcription, reducing FBI-1 and thereby de-repressing SLC16A3 and increasing lactate efflux to promote cancer cell growth.","method":"Transcription reporter assays (SLC16A3 promoter fusions), oligonucleotide pulldowns, ChIP assays, ectopic expression/knockdown of FBI-1 and RelA/p65 in colon cancer cells","journal":"Biochimica et Biophysica Acta – Gene Regulatory Mechanisms","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (reporter assay, ChIP, oligonucleotide pulldown, functional rescue), single lab","pmids":["31271899"],"is_preprint":false},{"year":2008,"finding":"In preimplantation mouse embryos, SLC16A3 (MCT4) localizes to the plasma membrane through the morula stage and maintains a nuclear distribution throughout preimplantation development; continued Slc16a3 mRNA expression is dependent on prior exposure to glucose.","method":"Immunofluorescence localization, RT-PCR expression analysis under varying glucose conditions in mouse embryos","journal":"Biology of Reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by immunofluorescence with functional glucose-dependence condition, single lab","pmids":["18385447"],"is_preprint":false},{"year":2022,"finding":"Both MCT1 (SLC16A1) and MCT4 (SLC16A3) mediate pH-dependent l-lactate uptake in hepatocellular carcinoma cell lines (HepG2, Huh-7); knockdown of MCT4 decreased l-lactate uptake, whereas knockdown of MCT2 had no effect; MCT4 expression is significantly elevated in HCC compared to normal hepatocytes.","method":"l-lactate uptake assays at pH 6.0, pharmacological inhibitors, siRNA knockdown of MCT1/2/4, kinetic analysis in HepG2 and Huh-7 cells","journal":"Biopharmaceutics & Drug Disposition","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional transport assay with selective inhibitors and siRNA knockdown, two cell lines, single lab","pmids":["36104287"],"is_preprint":false},{"year":2021,"finding":"The lncRNA LINC00035 recruits transcription factor CEBPB to the SLC16A3 promoter, increasing SLC16A3 transcription; elevated SLC16A3 drives glycolysis and reduces apoptosis in ovarian cancer cells. (NOTE: the original paper PMID:34671407 was subsequently retracted per PMID:37387995.)","method":"Luciferase reporter assay, RNA immunoprecipitation (RIP), RNA pulldown, rescue experiments in SKOV3/A2780 cells","journal":"Evidence-Based Complementary and Alternative Medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single set of methods, paper subsequently retracted","pmids":["34671407","37387995"],"is_preprint":false},{"year":2023,"finding":"A paralog-dependent isogenic cell assay (PARADISO) exploiting synthetic lethality between SLC16A1 and SLC16A3 enabled discovery of slCeMM1, a potent and paralog-selective SLC16A3 inhibitor confirmed as proteome-wide selective by chemoproteomics.","method":"Isogenic cell survival assay cascade, diversity-oriented library screen (~90,000 compounds), chemoproteomics","journal":"Cell Chemical Biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based functional assay with proteome-wide selectivity validation by chemoproteomics, single lab","pmids":["37516113"],"is_preprint":false},{"year":2024,"finding":"SLC16A3 overexpression in tumor cells promotes lactic acid production and efflux, suppresses CD8+ T cell function, and reduces response to anti-PD-1; genetic or pharmacological inhibition of SLC16A3 reduces glycolytic activity, lactic acid production, and reverses immunosuppressive tumor microenvironment to enhance anti-PD-1 efficacy.","method":"SLC16A3 overexpression and genetic/pharmacological inhibition in B16-F10 cells, lactic acid measurement, CD8+ T cell functional assays, in vivo tumor models with anti-PD-1","journal":"Cancer Letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with functional immune readouts in vitro and in vivo, single lab","pmids":["38522774"],"is_preprint":false},{"year":2025,"finding":"Mutant KRAS elevates SLC16A3 expression via the PI3K-AKT-mTORC1-HIF1α pathway; Casein Kinase 2 (CK2) directly phosphorylates SLC16A3 at Serine 436, and this phosphorylation is required for SLC16A3's oncogenic function in intrahepatic cholangiocarcinoma; CK2 inhibition reduced growth of KRAS-mutated iCCA xenografts and patient-derived organoids.","method":"Pathway inhibitor experiments (PI3K-AKT-mTOR), phosphorylation mapping, site-directed mutagenesis (S436), CK2 kinase assay, xenograft and patient-derived organoid models","journal":"Cancer Research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct phosphorylation identification with mutagenesis, upstream pathway delineation, in vivo validation, single lab with multiple orthogonal methods","pmids":["39854318"],"is_preprint":false},{"year":2024,"finding":"SLC16A3 knockdown in HCC cells decreases extracellular lactate, reverses hypoxia, inhibits ERK phosphorylation, and induces ferroptosis by increasing lipid peroxidation and ROS while decreasing GPX4, DHODH, and SLC7A11 expression.","method":"siRNA knockdown, Western blot for pathway proteins (ERK, GPX4, DHODH, SLC7A11), ROS/lipid peroxidation assays in HCC cell lines","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with multiple molecular readouts, single lab","pmids":["39303526"],"is_preprint":false},{"year":2025,"finding":"SLC16A3 interacts with AP1G1 (a clathrin adaptor protein involved in endocytosis); SLC16A3 determines membrane enrichment of AP1G1, and knockdown of SLC16A3 reduces AP1G1 membrane localization and decreases host cell susceptibility to diverse respiratory viruses.","method":"Metabolomics, proteomics, thermal proteome profiling, Co-IP/interaction assays, SLC16A3 knockdown with viral infection assays","journal":"Microbiology Spectrum","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — interaction identified by thermal proteome profiling and validated by knockdown with functional readout, single lab","pmids":["40919783"],"is_preprint":false},{"year":2025,"finding":"HIF1A transcriptionally activates SLC16A3; the HIF1A-SLC16A3 axis suppresses ferroptosis and confers gefitinib resistance in lung adenocarcinoma; SLC16A3 inhibition restored ferroptotic sensitivity in vivo. Lactate supplementation partially reversed ferroptosis induction caused by SLC16A3 knockdown, linking the transporter's lactate efflux function to ferroptosis resistance.","method":"JASPAR transcription factor prediction, luciferase reporter assay, ferroptosis indicators (lipid peroxidation, iron accumulation, mitochondrial depolarization), lactate rescue experiments, in vivo xenograft models","journal":"Frontiers in Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter confirms HIF1A-SLC16A3 axis, multiple ferroptosis readouts with lactate rescue, in vivo validation, single lab","pmids":["41293164"],"is_preprint":false},{"year":2026,"finding":"In TNBC cells, EGF signaling activates secretory autophagy via SEC22B; autophagosomes carry SLC16A3/MCT4 and its chaperone BSG/CD147 to the plasma membrane. EGF promotes LC3-SLC16A3 interaction, facilitating SLC16A3 trafficking to the plasma membrane and enhancing lactate efflux. Blockade of autophagy abolishes SLC16A3 surface localization, reduces lactate secretion, and suppresses lung metastasis in orthotopic mouse models.","method":"Proteomic profiling of purified autophagosomes, proximity ligation assay (PLA) for LC3-SLC16A3 interaction, TIRF microscopy for surface localization, autophagy blockade (genetic and pharmacological), in vivo orthotopic TNBC lung metastasis model","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — autophagosome proteomics, direct interaction assay, TIRF localization, in vivo metastasis model with multiple orthogonal methods, single lab","pmids":["41948828"],"is_preprint":false},{"year":2026,"finding":"SLC16A3-mediated lactate export activates GPR81 on macrophages to drive ERK-dependent M2 polarization and suppress CD8+ T cells; simultaneously, autocrine tumor GPR81 activation by exported lactate phosphorylates c-MYC at Ser62, preventing FBXW7-mediated degradation and sustaining a glycolytic feedback loop (upregulating LDHA, GLUT1, HIF1α) particularly in VHL-deficient ccRCC. Combining MCT4 inhibitor MSC-4381 with PD-1 blockade markedly reduced tumor volume in immunocompetent mice.","method":"In vivo CRISPR metabolic library screen in immunocompetent ccRCC model, SLC16A3 KO/OE cell lines, Seahorse metabolic assay, flow cytometry, lactate-treated macrophage assays, GPR81 antagonism/knockdown, RNA-seq, ubiquitination/phosphorylation analysis, tissue microarray","journal":"Balkan Medical Journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vivo CRISPR screen combined with multiple orthogonal mechanistic assays (phosphorylation, ubiquitination, GPR81 genetic suppression, in vivo combination therapy), single lab","pmids":["42028950"],"is_preprint":false},{"year":2025,"finding":"SLC16A3 knockdown-induced apoptosis in lung cancer cells is dependent on p38-MAPK pathway activation and caspase-3; pharmacological blockade of p38 (SB203580) attenuated apoptosis caused by SLC16A3 silencing, establishing a SLC16A3-p38-caspase-3 signaling axis.","method":"siRNA knockdown of SLC16A3, phospho-kinase array, pharmacological p38 inhibition (SB203580), caspase-3 activity assays, clonogenic survival assays","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phospho-kinase array plus pharmacological pathway rescue linking SLC16A3 to p38-caspase axis, single lab","pmids":["41475270"],"is_preprint":false},{"year":2025,"finding":"SLC16A3 in lung adenocarcinoma positively modulates intracellular and extracellular lactate levels and glycolysis; SLC16A3 overexpression promotes M2 macrophage polarization through lactate, and glycolysis inhibitors blocked this M2-promoting effect, placing glycolysis/lactate efflux downstream of SLC16A3 and upstream of macrophage polarization.","method":"Seahorse energy metabolism analyzer, glucose/lactate assay kits, pHrodo intracellular pH indicator, flow cytometry for macrophage polarization, ELISA for cytokines, rescue with glycolysis inhibitors, in vivo allograft tumor model with IHC","journal":"Cancer Immunology, Immunotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple metabolic assays, rescue experiment with glycolysis inhibitor, in vivo validation, single lab","pmids":["41432987"],"is_preprint":false}],"current_model":"SLC16A3 (MCT4) is an H⁺-coupled monocarboxylate cotransporter that exports lactate across the plasma membrane; its transcription is activated by HIF-1α (via HRE binding) and repressed by FBI-1/ZBTB7A, with NF-κB de-repressing it under hypoxia by downregulating ZBTB7A, while CpG methylation of its promoter suppresses expression; its transporter activity can be non-competitively inhibited by diclofenac; surface localization is regulated by EGF-driven secretory autophagy (LC3-SLC16A3 interaction); CK2 phosphorylates SLC16A3 at S436 to enhance its oncogenic function downstream of mutant KRAS-PI3K-AKT-mTORC1-HIF1α; and through lactate efflux, SLC16A3 activates GPR81-ERK-c-MYC autocrine loops, promotes M2 macrophage polarization, suppresses CD8⁺ T cells, and confers ferroptosis resistance, thereby driving tumor progression and immune evasion."},"narrative":{"mechanistic_narrative":"SLC16A3 (MCT4) is an H⁺-coupled, pH-dependent monocarboxylate transporter that exports lactate across the plasma membrane and thereby couples glycolytic metabolism to extracellular signaling in cancer [PMID:27236641, PMID:36104287]. It mediates l-lactate uptake/efflux with kinetics characterized in epithelial and hepatocellular carcinoma cells, and in polarized epithelium it functions specifically as a basolateral efflux transporter [PMID:26854723, PMID:36104287]; its lactate-transport activity is non-competitively inhibited by diclofenac and by paralog-selective small molecules developed against it [PMID:27236641, PMID:37516113]. Transcriptionally, SLC16A3 is a hypoxia-responsive gene directly activated by HIF-1α binding a promoter HRE, repressed by FBI-1/ZBTB7A, and de-repressed when NF-κB (RelA/p65) downregulates ZBTB7A; promoter CpG methylation independently silences its expression [PMID:23881922, PMID:31271899]. Beyond transcription, surface delivery and activity of the transporter are controlled post-transcriptionally: CK2 phosphorylates SLC16A3 at Ser436 downstream of mutant KRAS–PI3K–AKT–mTORC1–HIF1α to enable its oncogenic function [PMID:39854318], and EGF-driven secretory autophagy traffics SLC16A3 together with its CD147/BSG chaperone to the plasma membrane via an LC3–SLC16A3 interaction [PMID:41948828]. Functionally, SLC16A3-mediated lactate export drives tumor progression and immune evasion by activating GPR81–ERK–c-MYC autocrine loops, promoting M2 macrophage polarization, suppressing CD8⁺ T cells and limiting anti-PD-1 efficacy, and conferring resistance to ferroptosis and to gefitinib [PMID:38522774, PMID:41293164, PMID:42028950, PMID:41432987]. Loss of SLC16A3 reverses these phenotypes, inducing ferroptosis through loss of GPX4/DHODH/SLC7A11 and triggering p38-MAPK/caspase-3-dependent apoptosis [PMID:39303526, PMID:41475270].","teleology":[{"year":2008,"claim":"Established that SLC16A3/MCT4 is expressed and membrane-localized in a glucose-dependent manner during early development, the first link between its expression and metabolic substrate availability.","evidence":"Immunofluorescence and RT-PCR under varying glucose conditions in preimplantation mouse embryos","pmids":["18385447"],"confidence":"Medium","gaps":["Does not establish transport kinetics or H⁺-coupling","Nuclear distribution observed but unexplained mechanistically"]},{"year":2013,"claim":"Identified promoter CpG methylation as a transcriptional control point silencing MCT4 expression in renal cancer.","evidence":"Promoter reporter assays in RCC cell lines with methylation–expression correlation in patient cohorts","pmids":["23881922"],"confidence":"Medium","gaps":["Methylating/demethylating enzymes not identified","Does not connect methylation status to transporter activity or downstream phenotype"]},{"year":2016,"claim":"Directly demonstrated MCT4's transport function—l-lactate cotransport—and provided a pharmacological inhibitor (diclofenac) and a polarity assignment (basolateral efflux).","evidence":"Radiolabeled l-lactate uptake with kinetic inhibition in Caco-2, Xenopus oocyte expression, and transepithelial transport/immunofluorescence localization","pmids":["27236641","26854723"],"confidence":"High","gaps":["Stoichiometry of H⁺ coupling not quantified","Substrate range beyond lactate/ferulic acid not mapped"]},{"year":2019,"claim":"Resolved the hypoxia-responsive transcriptional circuit controlling SLC16A3: direct HIF-1α activation, ZBTB7A/FBI-1 repression, and NF-κB-mediated de-repression.","evidence":"Promoter reporter assays, ChIP, oligonucleotide pulldown, and knockdown/overexpression of FBI-1 and RelA/p65 in colon cancer cells","pmids":["31271899"],"confidence":"High","gaps":["Quantitative interplay between methylation and HIF/NF-κB inputs unresolved","Tissue-specificity of this circuit untested"]},{"year":2022,"claim":"Confirmed MCT4 as a functionally dominant lactate transporter in hepatocellular carcinoma, distinguishing it from MCT2.","evidence":"pH-dependent l-lactate uptake with selective inhibitors and siRNA knockdown of MCT1/2/4 in HepG2 and Huh-7","pmids":["36104287"],"confidence":"Medium","gaps":["Relative contributions of MCT1 vs MCT4 not fully separated","Single tumor type"]},{"year":2023,"claim":"Provided a paralog-selective chemical probe (slCeMM1) exploiting SLC16A1/SLC16A3 synthetic lethality, enabling specific pharmacological dissection of MCT4.","evidence":"Isogenic cell survival assay cascade, ~90,000-compound screen, and chemoproteomic selectivity validation","pmids":["37516113"],"confidence":"Medium","gaps":["Binding site on SLC16A3 not structurally defined","In vivo efficacy of probe not established here"]},{"year":2024,"claim":"Connected SLC16A3 lactate export to immune evasion, showing it suppresses CD8⁺ T cells and limits anti-PD-1 response.","evidence":"Overexpression and genetic/pharmacological inhibition in B16-F10 with lactate measurement, CD8⁺ T cell assays, and in vivo anti-PD-1 models","pmids":["38522774"],"confidence":"Medium","gaps":["Receptor mediating T cell suppression not defined in this study","Lactate vs acidification contribution not separated"]},{"year":2024,"claim":"Linked SLC16A3 lactate efflux to ferroptosis resistance via ERK signaling and the GPX4/DHODH/SLC7A11 axis.","evidence":"siRNA knockdown with ERK/GPX4/DHODH/SLC7A11 Western blots and ROS/lipid peroxidation assays in HCC cells","pmids":["39303526"],"confidence":"Medium","gaps":["Direct causal chain from lactate to GPX4 not dissected","No in vivo confirmation in this report"]},{"year":2025,"claim":"Identified post-translational regulation: CK2-mediated Ser436 phosphorylation downstream of mutant KRAS–PI3K–AKT–mTORC1–HIF1α is required for SLC16A3 oncogenicity.","evidence":"Pathway inhibitor experiments, phosphosite mapping, S436 mutagenesis, CK2 kinase assay, xenografts and patient-derived organoids in iCCA","pmids":["39854318"],"confidence":"High","gaps":["How S436 phosphorylation alters transport or trafficking mechanistically unresolved","Other phosphosites not excluded"]},{"year":2025,"claim":"Extended ferroptosis resistance to a HIF1A-SLC16A3 axis conferring gefitinib resistance, with lactate rescue establishing transporter function as the effector.","evidence":"TF prediction, luciferase reporter, ferroptosis indicators, lactate rescue, and xenografts in lung adenocarcinoma","pmids":["41293164"],"confidence":"Medium","gaps":["Mechanism by which lactate suppresses lipid peroxidation not defined","Single resistance context (gefitinib)"]},{"year":2025,"claim":"Defined a SLC16A3–p38-MAPK–caspase-3 axis explaining apoptosis upon transporter loss in lung cancer.","evidence":"siRNA knockdown, phospho-kinase array, p38 inhibition (SB203580), and caspase-3 activity/clonogenic assays","pmids":["41475270"],"confidence":"Medium","gaps":["Whether p38 activation is metabolic or transport-independent unclear","Link to ferroptosis pathway not integrated"]},{"year":2025,"claim":"Placed glycolysis/lactate efflux downstream of SLC16A3 and upstream of M2 macrophage polarization in lung adenocarcinoma.","evidence":"Seahorse, glucose/lactate assays, pHrodo, flow cytometry, glycolysis-inhibitor rescue, and in vivo allograft model","pmids":["41432987"],"confidence":"Medium","gaps":["Receptor coupling lactate to macrophages not identified here","Cytokine mediators only partially characterized"]},{"year":2025,"claim":"Revealed a non-transport interaction with the clathrin adaptor AP1G1 that controls AP1G1 membrane enrichment and host susceptibility to respiratory viruses, broadening SLC16A3 function beyond metabolism.","evidence":"Metabolomics, proteomics, thermal proteome profiling, Co-IP, and knockdown with viral infection assays","pmids":["40919783"],"confidence":"Medium","gaps":["Single Co-IP/TPP interaction without reciprocal validation","Whether this requires transport activity is untested"]},{"year":2026,"claim":"Established that EGF-driven secretory autophagy traffics SLC16A3 and its CD147/BSG chaperone to the plasma membrane via LC3 interaction, a post-transcriptional surface-delivery mechanism driving metastasis.","evidence":"Autophagosome proteomics, LC3-SLC16A3 PLA, TIRF surface imaging, autophagy blockade, and orthotopic TNBC lung-metastasis models","pmids":["41948828"],"confidence":"High","gaps":["LC3-SLC16A3 binding interface undefined","Generality across non-TNBC tumors untested"]},{"year":2026,"claim":"Integrated SLC16A3 lactate export into GPR81-driven autocrine and paracrine circuits—ERK/M2 polarization, CD8⁺ suppression, and c-MYC Ser62 stabilization sustaining glycolysis—and validated MCT4 inhibition plus PD-1 blockade in vivo.","evidence":"In vivo CRISPR metabolic screen, KO/OE lines, Seahorse, flow cytometry, GPR81 antagonism/knockdown, ubiquitination/phosphorylation analysis, and combination therapy in immunocompetent ccRCC","pmids":["42028950"],"confidence":"High","gaps":["Direct GPR81-c-MYC signaling intermediates incompletely mapped","VHL-deficiency dependence not generalized beyond ccRCC"]},{"year":null,"claim":"It remains unknown how Ser436 phosphorylation, LC3-mediated trafficking, and the AP1G1 interaction mechanistically alter the transporter's structure or transport cycle, and no structural model of SLC16A3 with its chaperone or inhibitors is available in the corpus.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural/biophysical model of the transport mechanism","Coupling between post-translational regulation and transport kinetics undefined","Non-metabolic (AP1G1/viral) role not mechanistically separated from transport"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[1,2,5]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[1,5]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,4,13]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,16]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[1,2,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,9,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,14,16]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,15]}],"complexes":[],"partners":["BSG","AP1G1","MAP1LC3B","CSNK2A1","GPR81"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15427","full_name":"Monocarboxylate transporter 4","aliases":["Solute carrier family 16 member 3"],"length_aa":465,"mass_kda":49.5,"function":"Proton-dependent transporter of monocarboxylates such as L-lactate and pyruvate (PubMed:11101640, PubMed:23935841, PubMed:31719150). Plays a predominant role in L-lactate efflux from highly glycolytic cells (By similarity)","subcellular_location":"Cell membrane; Basolateral cell membrane","url":"https://www.uniprot.org/uniprotkb/O15427/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC16A3","classification":"Not Classified","n_dependent_lines":36,"n_total_lines":1208,"dependency_fraction":0.029801324503311258},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SLC16A3","total_profiled":1310},"omim":[{"mim_id":"603880","title":"SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 6; SLC16A6","url":"https://www.omim.org/entry/603880"},{"mim_id":"603879","title":"SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 5; SLC16A5","url":"https://www.omim.org/entry/603879"},{"mim_id":"603878","title":"SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 4; SLC16A4","url":"https://www.omim.org/entry/603878"},{"mim_id":"603877","title":"SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 3; SLC16A3","url":"https://www.omim.org/entry/603877"},{"mim_id":"600682","title":"SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 1; SLC16A1","url":"https://www.omim.org/entry/600682"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nuclear membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":134.4}],"url":"https://www.proteinatlas.org/search/SLC16A3"},"hgnc":{"alias_symbol":["MCT3","MCT4"],"prev_symbol":[]},"alphafold":{"accession":"O15427","domains":[{"cath_id":"1.20.1250.20","chopping":"16-200","consensus_level":"medium","plddt":94.0817,"start":16,"end":200},{"cath_id":"1.20.1250.20","chopping":"219-412","consensus_level":"medium","plddt":92.2231,"start":219,"end":412}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15427","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15427-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15427-F1-predicted_aligned_error_v6.png","plddt_mean":83.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC16A3","jax_strain_url":"https://www.jax.org/strain/search?query=SLC16A3"},"sequence":{"accession":"O15427","fasta_url":"https://rest.uniprot.org/uniprotkb/O15427.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15427/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15427"}},"corpus_meta":[{"pmid":"23881922","id":"PMC_23881922","title":"DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23881922","citation_count":88,"is_preprint":false},{"pmid":"38522774","id":"PMC_38522774","title":"Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38522774","citation_count":45,"is_preprint":false},{"pmid":"27236641","id":"PMC_27236641","title":"Effect of diclofenac on SLC16A3/MCT4 by the Caco-2 cell line.","date":"2016","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/27236641","citation_count":41,"is_preprint":false},{"pmid":"26854723","id":"PMC_26854723","title":"Butyric acid increases transepithelial transport of ferulic acid through upregulation of the monocarboxylate transporters SLC16A1 (MCT1) and SLC16A3 (MCT4).","date":"2016","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/26854723","citation_count":38,"is_preprint":false},{"pmid":"31271899","id":"PMC_31271899","title":"Hypoxia-induced RelA/p65 derepresses SLC16A3 (MCT4) by downregulating ZBTB7A.","date":"2019","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/31271899","citation_count":36,"is_preprint":false},{"pmid":"35509603","id":"PMC_35509603","title":"Lactate Transporter SLC16A3 (MCT4) as an Onco-Immunological Biomarker Associating Tumor Microenvironment and Immune Responses in Lung Cancer.","date":"2022","source":"International journal of general medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35509603","citation_count":29,"is_preprint":false},{"pmid":"18385447","id":"PMC_18385447","title":"Characterization and regulation of monocarboxylate cotransporters Slc16a7 and Slc16a3 in preimplantation mouse embryos.","date":"2008","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/18385447","citation_count":23,"is_preprint":false},{"pmid":"36104287","id":"PMC_36104287","title":"Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l-lactate transport in the hepatocellular carcinoma cell line.","date":"2022","source":"Biopharmaceutics & drug disposition","url":"https://pubmed.ncbi.nlm.nih.gov/36104287","citation_count":14,"is_preprint":false},{"pmid":"34671407","id":"PMC_34671407","title":"LINC00035 Transcriptional Regulation of SLC16A3 via CEBPB Affects Glycolysis and Cell Apoptosis in Ovarian Cancer.","date":"2021","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/34671407","citation_count":12,"is_preprint":false},{"pmid":"39303526","id":"PMC_39303526","title":"Knockdown of SLC16A3 decreases extracellular lactate concentration in hepatocellular carcinoma, alleviates hypoxia and induces ferroptosis.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39303526","citation_count":10,"is_preprint":false},{"pmid":"37516113","id":"PMC_37516113","title":"Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors.","date":"2023","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/37516113","citation_count":9,"is_preprint":false},{"pmid":"37895298","id":"PMC_37895298","title":"Identification of Intron Retention in the Slc16a3 Gene Transcript Encoding the Transporter MCT4 in the Brain of Aged and Alzheimer-Disease Model (APPswePS1dE9) Mice.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/37895298","citation_count":8,"is_preprint":false},{"pmid":"30177396","id":"PMC_30177396","title":"Genetic variations in the monocarboxylate transporter genes (SLC16A1, SLC16A3, and SLC16A11) in the Japanese population.","date":"2018","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/30177396","citation_count":8,"is_preprint":false},{"pmid":"22240841","id":"PMC_22240841","title":"Genetic variations of the MCT4 (SLC16A3) gene in the Chinese and Indian populations of Singapore.","date":"2012","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/22240841","citation_count":7,"is_preprint":false},{"pmid":"39743824","id":"PMC_39743824","title":"Precision Nanotherapy for Spinal Cord Injury: Modulating SLC16A3 With Methylprednisolone-Loaded Nanoparticles.","date":"2024","source":"Neurospine","url":"https://pubmed.ncbi.nlm.nih.gov/39743824","citation_count":6,"is_preprint":false},{"pmid":"39854318","id":"PMC_39854318","title":"Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression.","date":"2025","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39854318","citation_count":5,"is_preprint":false},{"pmid":"39656344","id":"PMC_39656344","title":"Integrated Single-Cell and Spatial Transcriptome Reveal Metabolic Gene SLC16A3 as a Key Regulator of Immune Suppression in Hepatocellular Carcinoma.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39656344","citation_count":4,"is_preprint":false},{"pmid":"40927315","id":"PMC_40927315","title":"SLC16A3 (MCT4) expression in tumor immunity and Metabolism: Insights from pan-cancer analysis.","date":"2025","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/40927315","citation_count":2,"is_preprint":false},{"pmid":"41475270","id":"PMC_41475270","title":"SLC16A3 as a novel therapeutic target for overcoming radioresistance and chemoresistance in lung cancer.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/41475270","citation_count":2,"is_preprint":false},{"pmid":"41432987","id":"PMC_41432987","title":"SLC16A3 in lung adenocarcinoma regulates glycolysis and lactate release to facilitate M2 polarization of tumor-associated macrophages : Short Title: SLC16A3 reinforces macrophage M2 polarization through glycolysis.","date":"2025","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/41432987","citation_count":1,"is_preprint":false},{"pmid":"41293164","id":"PMC_41293164","title":"SLC16A3 drives lung adenocarcinoma progression and gefitinib resistance through coordinated regulation of ferroptosis and lactate metabolism.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41293164","citation_count":0,"is_preprint":false},{"pmid":"42028950","id":"PMC_42028950","title":"SLC16A3-Induced Lactate Remodeling Drives Immune Evasion in Clear Cell Renal Cell Carcinoma via an Autocrine GPR81-ERK-c-MYC Feedback Loop.","date":"2026","source":"Balkan medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/42028950","citation_count":0,"is_preprint":false},{"pmid":"41948828","id":"PMC_41948828","title":"Secretory autophagy mediates SLC16A3/MCT4-dependent lactate secretion to drive metastatic progression in triple-negative breast cancer.","date":"2026","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/41948828","citation_count":0,"is_preprint":false},{"pmid":"37387995","id":"PMC_37387995","title":"Retracted: LINC00035 Transcriptional Regulation of SLC16A3 via CEBPB Affects Glycolysis and Cell Apoptosis in Ovarian Cancer.","date":"2023","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/37387995","citation_count":0,"is_preprint":false},{"pmid":"40919783","id":"PMC_40919783","title":"Attenuate host susceptibility to respiratory virus invasion by inhibiting interactions between host proteins SLC16A3 and AP1G1.","date":"2025","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/40919783","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16506,"output_tokens":4652,"usd":0.059649,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12764,"output_tokens":4804,"usd":0.09196,"stage2_stop_reason":"end_turn"},"total_usd":0.151609,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"DNA methylation of the SLC16A3 promoter regulates MCT4 expression in renal cancer; promoter activity assays in RCC cell lines confirmed that methylation at specific CpG sites suppresses SLC16A3/MCT4 transcription.\",\n      \"method\": \"Promoter activity assays in RCC cell lines, correlation of CpG methylation with mRNA expression in patient cohorts\",\n      \"journal\": \"Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assays in four cell lines, validated in three independent cohorts, single lab\",\n      \"pmids\": [\"23881922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MCT4 (SLC16A3) mediates l-lactate transport in Caco-2 cells; diclofenac non-competitively inhibits MCT4-mediated l-lactate uptake with an inhibition constant of 20 µM, validated in Xenopus oocyte expression system.\",\n      \"method\": \"Radiolabeled l-lactate uptake assay in Caco-2 cells, kinetic inhibition analysis, Xenopus oocyte expression system\",\n      \"journal\": \"Drug Metabolism and Pharmacokinetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro transport assay with kinetic analysis plus orthogonal Xenopus oocyte validation, single lab\",\n      \"pmids\": [\"27236641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Butyric acid upregulates SLC16A3 (MCT4) protein and mRNA in Caco-2 cells; MCT4 localizes exclusively to the lateral plasma membrane and functions as a basolateral efflux transporter for ferulic acid, while MCT1 mediates apical uptake.\",\n      \"method\": \"mRNA/protein quantification, immunofluorescence localization, transepithelial transport assays in Caco-2 cells\",\n      \"journal\": \"Archives of Biochemistry and Biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by immunofluorescence tied to functional transport assay, single lab\",\n      \"pmids\": [\"26854723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Under hypoxia, HIF-1α directly activates SLC16A3 transcription by binding a hypoxia-response element (HRE) in the promoter; FBI-1 (ZBTB7A) represses SLC16A3 by binding FREs and HREs. NF-κB (RelA/p65) represses ZBTB7A transcription, reducing FBI-1 and thereby de-repressing SLC16A3 and increasing lactate efflux to promote cancer cell growth.\",\n      \"method\": \"Transcription reporter assays (SLC16A3 promoter fusions), oligonucleotide pulldowns, ChIP assays, ectopic expression/knockdown of FBI-1 and RelA/p65 in colon cancer cells\",\n      \"journal\": \"Biochimica et Biophysica Acta – Gene Regulatory Mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (reporter assay, ChIP, oligonucleotide pulldown, functional rescue), single lab\",\n      \"pmids\": [\"31271899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In preimplantation mouse embryos, SLC16A3 (MCT4) localizes to the plasma membrane through the morula stage and maintains a nuclear distribution throughout preimplantation development; continued Slc16a3 mRNA expression is dependent on prior exposure to glucose.\",\n      \"method\": \"Immunofluorescence localization, RT-PCR expression analysis under varying glucose conditions in mouse embryos\",\n      \"journal\": \"Biology of Reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by immunofluorescence with functional glucose-dependence condition, single lab\",\n      \"pmids\": [\"18385447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Both MCT1 (SLC16A1) and MCT4 (SLC16A3) mediate pH-dependent l-lactate uptake in hepatocellular carcinoma cell lines (HepG2, Huh-7); knockdown of MCT4 decreased l-lactate uptake, whereas knockdown of MCT2 had no effect; MCT4 expression is significantly elevated in HCC compared to normal hepatocytes.\",\n      \"method\": \"l-lactate uptake assays at pH 6.0, pharmacological inhibitors, siRNA knockdown of MCT1/2/4, kinetic analysis in HepG2 and Huh-7 cells\",\n      \"journal\": \"Biopharmaceutics & Drug Disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional transport assay with selective inhibitors and siRNA knockdown, two cell lines, single lab\",\n      \"pmids\": [\"36104287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The lncRNA LINC00035 recruits transcription factor CEBPB to the SLC16A3 promoter, increasing SLC16A3 transcription; elevated SLC16A3 drives glycolysis and reduces apoptosis in ovarian cancer cells. (NOTE: the original paper PMID:34671407 was subsequently retracted per PMID:37387995.)\",\n      \"method\": \"Luciferase reporter assay, RNA immunoprecipitation (RIP), RNA pulldown, rescue experiments in SKOV3/A2780 cells\",\n      \"journal\": \"Evidence-Based Complementary and Alternative Medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single set of methods, paper subsequently retracted\",\n      \"pmids\": [\"34671407\", \"37387995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A paralog-dependent isogenic cell assay (PARADISO) exploiting synthetic lethality between SLC16A1 and SLC16A3 enabled discovery of slCeMM1, a potent and paralog-selective SLC16A3 inhibitor confirmed as proteome-wide selective by chemoproteomics.\",\n      \"method\": \"Isogenic cell survival assay cascade, diversity-oriented library screen (~90,000 compounds), chemoproteomics\",\n      \"journal\": \"Cell Chemical Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based functional assay with proteome-wide selectivity validation by chemoproteomics, single lab\",\n      \"pmids\": [\"37516113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SLC16A3 overexpression in tumor cells promotes lactic acid production and efflux, suppresses CD8+ T cell function, and reduces response to anti-PD-1; genetic or pharmacological inhibition of SLC16A3 reduces glycolytic activity, lactic acid production, and reverses immunosuppressive tumor microenvironment to enhance anti-PD-1 efficacy.\",\n      \"method\": \"SLC16A3 overexpression and genetic/pharmacological inhibition in B16-F10 cells, lactic acid measurement, CD8+ T cell functional assays, in vivo tumor models with anti-PD-1\",\n      \"journal\": \"Cancer Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with functional immune readouts in vitro and in vivo, single lab\",\n      \"pmids\": [\"38522774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Mutant KRAS elevates SLC16A3 expression via the PI3K-AKT-mTORC1-HIF1α pathway; Casein Kinase 2 (CK2) directly phosphorylates SLC16A3 at Serine 436, and this phosphorylation is required for SLC16A3's oncogenic function in intrahepatic cholangiocarcinoma; CK2 inhibition reduced growth of KRAS-mutated iCCA xenografts and patient-derived organoids.\",\n      \"method\": \"Pathway inhibitor experiments (PI3K-AKT-mTOR), phosphorylation mapping, site-directed mutagenesis (S436), CK2 kinase assay, xenograft and patient-derived organoid models\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct phosphorylation identification with mutagenesis, upstream pathway delineation, in vivo validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39854318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SLC16A3 knockdown in HCC cells decreases extracellular lactate, reverses hypoxia, inhibits ERK phosphorylation, and induces ferroptosis by increasing lipid peroxidation and ROS while decreasing GPX4, DHODH, and SLC7A11 expression.\",\n      \"method\": \"siRNA knockdown, Western blot for pathway proteins (ERK, GPX4, DHODH, SLC7A11), ROS/lipid peroxidation assays in HCC cell lines\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with multiple molecular readouts, single lab\",\n      \"pmids\": [\"39303526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SLC16A3 interacts with AP1G1 (a clathrin adaptor protein involved in endocytosis); SLC16A3 determines membrane enrichment of AP1G1, and knockdown of SLC16A3 reduces AP1G1 membrane localization and decreases host cell susceptibility to diverse respiratory viruses.\",\n      \"method\": \"Metabolomics, proteomics, thermal proteome profiling, Co-IP/interaction assays, SLC16A3 knockdown with viral infection assays\",\n      \"journal\": \"Microbiology Spectrum\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — interaction identified by thermal proteome profiling and validated by knockdown with functional readout, single lab\",\n      \"pmids\": [\"40919783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HIF1A transcriptionally activates SLC16A3; the HIF1A-SLC16A3 axis suppresses ferroptosis and confers gefitinib resistance in lung adenocarcinoma; SLC16A3 inhibition restored ferroptotic sensitivity in vivo. Lactate supplementation partially reversed ferroptosis induction caused by SLC16A3 knockdown, linking the transporter's lactate efflux function to ferroptosis resistance.\",\n      \"method\": \"JASPAR transcription factor prediction, luciferase reporter assay, ferroptosis indicators (lipid peroxidation, iron accumulation, mitochondrial depolarization), lactate rescue experiments, in vivo xenograft models\",\n      \"journal\": \"Frontiers in Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter confirms HIF1A-SLC16A3 axis, multiple ferroptosis readouts with lactate rescue, in vivo validation, single lab\",\n      \"pmids\": [\"41293164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"In TNBC cells, EGF signaling activates secretory autophagy via SEC22B; autophagosomes carry SLC16A3/MCT4 and its chaperone BSG/CD147 to the plasma membrane. EGF promotes LC3-SLC16A3 interaction, facilitating SLC16A3 trafficking to the plasma membrane and enhancing lactate efflux. Blockade of autophagy abolishes SLC16A3 surface localization, reduces lactate secretion, and suppresses lung metastasis in orthotopic mouse models.\",\n      \"method\": \"Proteomic profiling of purified autophagosomes, proximity ligation assay (PLA) for LC3-SLC16A3 interaction, TIRF microscopy for surface localization, autophagy blockade (genetic and pharmacological), in vivo orthotopic TNBC lung metastasis model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — autophagosome proteomics, direct interaction assay, TIRF localization, in vivo metastasis model with multiple orthogonal methods, single lab\",\n      \"pmids\": [\"41948828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SLC16A3-mediated lactate export activates GPR81 on macrophages to drive ERK-dependent M2 polarization and suppress CD8+ T cells; simultaneously, autocrine tumor GPR81 activation by exported lactate phosphorylates c-MYC at Ser62, preventing FBXW7-mediated degradation and sustaining a glycolytic feedback loop (upregulating LDHA, GLUT1, HIF1α) particularly in VHL-deficient ccRCC. Combining MCT4 inhibitor MSC-4381 with PD-1 blockade markedly reduced tumor volume in immunocompetent mice.\",\n      \"method\": \"In vivo CRISPR metabolic library screen in immunocompetent ccRCC model, SLC16A3 KO/OE cell lines, Seahorse metabolic assay, flow cytometry, lactate-treated macrophage assays, GPR81 antagonism/knockdown, RNA-seq, ubiquitination/phosphorylation analysis, tissue microarray\",\n      \"journal\": \"Balkan Medical Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vivo CRISPR screen combined with multiple orthogonal mechanistic assays (phosphorylation, ubiquitination, GPR81 genetic suppression, in vivo combination therapy), single lab\",\n      \"pmids\": [\"42028950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SLC16A3 knockdown-induced apoptosis in lung cancer cells is dependent on p38-MAPK pathway activation and caspase-3; pharmacological blockade of p38 (SB203580) attenuated apoptosis caused by SLC16A3 silencing, establishing a SLC16A3-p38-caspase-3 signaling axis.\",\n      \"method\": \"siRNA knockdown of SLC16A3, phospho-kinase array, pharmacological p38 inhibition (SB203580), caspase-3 activity assays, clonogenic survival assays\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-kinase array plus pharmacological pathway rescue linking SLC16A3 to p38-caspase axis, single lab\",\n      \"pmids\": [\"41475270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SLC16A3 in lung adenocarcinoma positively modulates intracellular and extracellular lactate levels and glycolysis; SLC16A3 overexpression promotes M2 macrophage polarization through lactate, and glycolysis inhibitors blocked this M2-promoting effect, placing glycolysis/lactate efflux downstream of SLC16A3 and upstream of macrophage polarization.\",\n      \"method\": \"Seahorse energy metabolism analyzer, glucose/lactate assay kits, pHrodo intracellular pH indicator, flow cytometry for macrophage polarization, ELISA for cytokines, rescue with glycolysis inhibitors, in vivo allograft tumor model with IHC\",\n      \"journal\": \"Cancer Immunology, Immunotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple metabolic assays, rescue experiment with glycolysis inhibitor, in vivo validation, single lab\",\n      \"pmids\": [\"41432987\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SLC16A3 (MCT4) is an H⁺-coupled monocarboxylate cotransporter that exports lactate across the plasma membrane; its transcription is activated by HIF-1α (via HRE binding) and repressed by FBI-1/ZBTB7A, with NF-κB de-repressing it under hypoxia by downregulating ZBTB7A, while CpG methylation of its promoter suppresses expression; its transporter activity can be non-competitively inhibited by diclofenac; surface localization is regulated by EGF-driven secretory autophagy (LC3-SLC16A3 interaction); CK2 phosphorylates SLC16A3 at S436 to enhance its oncogenic function downstream of mutant KRAS-PI3K-AKT-mTORC1-HIF1α; and through lactate efflux, SLC16A3 activates GPR81-ERK-c-MYC autocrine loops, promotes M2 macrophage polarization, suppresses CD8⁺ T cells, and confers ferroptosis resistance, thereby driving tumor progression and immune evasion.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SLC16A3 (MCT4) is an H⁺-coupled, pH-dependent monocarboxylate transporter that exports lactate across the plasma membrane and thereby couples glycolytic metabolism to extracellular signaling in cancer [#1, #5]. It mediates l-lactate uptake/efflux with kinetics characterized in epithelial and hepatocellular carcinoma cells, and in polarized epithelium it functions specifically as a basolateral efflux transporter [#2, #5]; its lactate-transport activity is non-competitively inhibited by diclofenac and by paralog-selective small molecules developed against it [#1, #7]. Transcriptionally, SLC16A3 is a hypoxia-responsive gene directly activated by HIF-1α binding a promoter HRE, repressed by FBI-1/ZBTB7A, and de-repressed when NF-κB (RelA/p65) downregulates ZBTB7A; promoter CpG methylation independently silences its expression [#0, #3]. Beyond transcription, surface delivery and activity of the transporter are controlled post-transcriptionally: CK2 phosphorylates SLC16A3 at Ser436 downstream of mutant KRAS–PI3K–AKT–mTORC1–HIF1α to enable its oncogenic function [#9], and EGF-driven secretory autophagy traffics SLC16A3 together with its CD147/BSG chaperone to the plasma membrane via an LC3–SLC16A3 interaction [#13]. Functionally, SLC16A3-mediated lactate export drives tumor progression and immune evasion by activating GPR81–ERK–c-MYC autocrine loops, promoting M2 macrophage polarization, suppressing CD8⁺ T cells and limiting anti-PD-1 efficacy, and conferring resistance to ferroptosis and to gefitinib [#8, #12, #14, #16]. Loss of SLC16A3 reverses these phenotypes, inducing ferroptosis through loss of GPX4/DHODH/SLC7A11 and triggering p38-MAPK/caspase-3-dependent apoptosis [#10, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established that SLC16A3/MCT4 is expressed and membrane-localized in a glucose-dependent manner during early development, the first link between its expression and metabolic substrate availability.\",\n      \"evidence\": \"Immunofluorescence and RT-PCR under varying glucose conditions in preimplantation mouse embryos\",\n      \"pmids\": [\"18385447\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not establish transport kinetics or H⁺-coupling\", \"Nuclear distribution observed but unexplained mechanistically\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified promoter CpG methylation as a transcriptional control point silencing MCT4 expression in renal cancer.\",\n      \"evidence\": \"Promoter reporter assays in RCC cell lines with methylation–expression correlation in patient cohorts\",\n      \"pmids\": [\"23881922\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Methylating/demethylating enzymes not identified\", \"Does not connect methylation status to transporter activity or downstream phenotype\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Directly demonstrated MCT4's transport function—l-lactate cotransport—and provided a pharmacological inhibitor (diclofenac) and a polarity assignment (basolateral efflux).\",\n      \"evidence\": \"Radiolabeled l-lactate uptake with kinetic inhibition in Caco-2, Xenopus oocyte expression, and transepithelial transport/immunofluorescence localization\",\n      \"pmids\": [\"27236641\", \"26854723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of H⁺ coupling not quantified\", \"Substrate range beyond lactate/ferulic acid not mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Resolved the hypoxia-responsive transcriptional circuit controlling SLC16A3: direct HIF-1α activation, ZBTB7A/FBI-1 repression, and NF-κB-mediated de-repression.\",\n      \"evidence\": \"Promoter reporter assays, ChIP, oligonucleotide pulldown, and knockdown/overexpression of FBI-1 and RelA/p65 in colon cancer cells\",\n      \"pmids\": [\"31271899\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative interplay between methylation and HIF/NF-κB inputs unresolved\", \"Tissue-specificity of this circuit untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Confirmed MCT4 as a functionally dominant lactate transporter in hepatocellular carcinoma, distinguishing it from MCT2.\",\n      \"evidence\": \"pH-dependent l-lactate uptake with selective inhibitors and siRNA knockdown of MCT1/2/4 in HepG2 and Huh-7\",\n      \"pmids\": [\"36104287\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contributions of MCT1 vs MCT4 not fully separated\", \"Single tumor type\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided a paralog-selective chemical probe (slCeMM1) exploiting SLC16A1/SLC16A3 synthetic lethality, enabling specific pharmacological dissection of MCT4.\",\n      \"evidence\": \"Isogenic cell survival assay cascade, ~90,000-compound screen, and chemoproteomic selectivity validation\",\n      \"pmids\": [\"37516113\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding site on SLC16A3 not structurally defined\", \"In vivo efficacy of probe not established here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected SLC16A3 lactate export to immune evasion, showing it suppresses CD8⁺ T cells and limits anti-PD-1 response.\",\n      \"evidence\": \"Overexpression and genetic/pharmacological inhibition in B16-F10 with lactate measurement, CD8⁺ T cell assays, and in vivo anti-PD-1 models\",\n      \"pmids\": [\"38522774\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating T cell suppression not defined in this study\", \"Lactate vs acidification contribution not separated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked SLC16A3 lactate efflux to ferroptosis resistance via ERK signaling and the GPX4/DHODH/SLC7A11 axis.\",\n      \"evidence\": \"siRNA knockdown with ERK/GPX4/DHODH/SLC7A11 Western blots and ROS/lipid peroxidation assays in HCC cells\",\n      \"pmids\": [\"39303526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct causal chain from lactate to GPX4 not dissected\", \"No in vivo confirmation in this report\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified post-translational regulation: CK2-mediated Ser436 phosphorylation downstream of mutant KRAS–PI3K–AKT–mTORC1–HIF1α is required for SLC16A3 oncogenicity.\",\n      \"evidence\": \"Pathway inhibitor experiments, phosphosite mapping, S436 mutagenesis, CK2 kinase assay, xenografts and patient-derived organoids in iCCA\",\n      \"pmids\": [\"39854318\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How S436 phosphorylation alters transport or trafficking mechanistically unresolved\", \"Other phosphosites not excluded\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended ferroptosis resistance to a HIF1A-SLC16A3 axis conferring gefitinib resistance, with lactate rescue establishing transporter function as the effector.\",\n      \"evidence\": \"TF prediction, luciferase reporter, ferroptosis indicators, lactate rescue, and xenografts in lung adenocarcinoma\",\n      \"pmids\": [\"41293164\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which lactate suppresses lipid peroxidation not defined\", \"Single resistance context (gefitinib)\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined a SLC16A3–p38-MAPK–caspase-3 axis explaining apoptosis upon transporter loss in lung cancer.\",\n      \"evidence\": \"siRNA knockdown, phospho-kinase array, p38 inhibition (SB203580), and caspase-3 activity/clonogenic assays\",\n      \"pmids\": [\"41475270\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether p38 activation is metabolic or transport-independent unclear\", \"Link to ferroptosis pathway not integrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placed glycolysis/lactate efflux downstream of SLC16A3 and upstream of M2 macrophage polarization in lung adenocarcinoma.\",\n      \"evidence\": \"Seahorse, glucose/lactate assays, pHrodo, flow cytometry, glycolysis-inhibitor rescue, and in vivo allograft model\",\n      \"pmids\": [\"41432987\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor coupling lactate to macrophages not identified here\", \"Cytokine mediators only partially characterized\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed a non-transport interaction with the clathrin adaptor AP1G1 that controls AP1G1 membrane enrichment and host susceptibility to respiratory viruses, broadening SLC16A3 function beyond metabolism.\",\n      \"evidence\": \"Metabolomics, proteomics, thermal proteome profiling, Co-IP, and knockdown with viral infection assays\",\n      \"pmids\": [\"40919783\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP/TPP interaction without reciprocal validation\", \"Whether this requires transport activity is untested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Established that EGF-driven secretory autophagy traffics SLC16A3 and its CD147/BSG chaperone to the plasma membrane via LC3 interaction, a post-transcriptional surface-delivery mechanism driving metastasis.\",\n      \"evidence\": \"Autophagosome proteomics, LC3-SLC16A3 PLA, TIRF surface imaging, autophagy blockade, and orthotopic TNBC lung-metastasis models\",\n      \"pmids\": [\"41948828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"LC3-SLC16A3 binding interface undefined\", \"Generality across non-TNBC tumors untested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Integrated SLC16A3 lactate export into GPR81-driven autocrine and paracrine circuits—ERK/M2 polarization, CD8⁺ suppression, and c-MYC Ser62 stabilization sustaining glycolysis—and validated MCT4 inhibition plus PD-1 blockade in vivo.\",\n      \"evidence\": \"In vivo CRISPR metabolic screen, KO/OE lines, Seahorse, flow cytometry, GPR81 antagonism/knockdown, ubiquitination/phosphorylation analysis, and combination therapy in immunocompetent ccRCC\",\n      \"pmids\": [\"42028950\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct GPR81-c-MYC signaling intermediates incompletely mapped\", \"VHL-deficiency dependence not generalized beyond ccRCC\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how Ser436 phosphorylation, LC3-mediated trafficking, and the AP1G1 interaction mechanistically alter the transporter's structure or transport cycle, and no structural model of SLC16A3 with its chaperone or inhibitors is available in the corpus.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural/biophysical model of the transport mechanism\", \"Coupling between post-translational regulation and transport kinetics undefined\", \"Non-metabolic (AP1G1/viral) role not mechanistically separated from transport\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [1, 2, 5]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [1, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 4, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 16]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [1, 2, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 9, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 14, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BSG\", \"AP1G1\", \"MAP1LC3B\", \"CSNK2A1\", \"GPR81\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}